Monthly FDA ReviewsUncategorized

September 2026 FDA Form 483 Review: Selected Findings

FDA Inspections Team

September 2026 Form 483 review: selected public documents issued in September describe concerns involving dynamic airflow studies, laboratory controls, investigation practices, and quality oversight. The examples below concern outsourcing facilities; they are not a cross-industry ranking.

Which dates does this review use?

This article reviews Form 483s issued in September and available for review by October 20. It does not claim that both were published during September. FDA’s reading room lists Right Value Drug Stores’ record as issued September 8 and published September 30; RC Outsourcing’s record was issued September 3 and published October 6. Check the FDA reading-room entries.

A Form 483 contains investigator observations, not a final agency determination. Public releases are selective. A missing record is not proof that no inspection occurred, and publication dates should not be used as inspection dates. FDA explains the purpose and limits of Form 483.

RC Outsourcing: aseptic process evidence

The September 3 Form 483 for RC Outsourcing LLC in Lowellville, Ohio describes concerns with airflow visualization, media-fill representation of operations, cleaning procedures, and sterility-failure investigations. Investigators also noted the release of other batches made under the same conditions as rejected batches without adequate scientific justification or documented risk mitigation.

Readiness question: can the site connect a failed result to a documented investigation of potentially related production, rather than treating rejection of one batch as the end of the review? This is our practical interpretation, not an additional finding about this firm.

Right Value Drug Stores: quality oversight and follow-through

The September 8 Form 483 identifies Right Value Drug Stores LLC at its Irving, Texas facility. Investigators described inadequate dynamic smoke-study evidence, missing dissolution and hardness/friability testing for estradiol pellet release, and quality-unit follow-through concerns. Examples included incomplete implementation of corrective actions across affected master batch records and use of a contract laboratory before qualification was complete.

Readiness question: can an action owner show where a corrective action was applied, which related records were reviewed, and what objective evidence supports closure? The public document identifies some repeat observations; that does not justify assuming the status of remediation today.

Use the documents without over-interpreting them

  • Read the original observation and its examples before assigning an internal action.
  • Keep the document’s scope, site, and date attached to any training note.
  • Separate investigator observations from your own gap assessment.
  • Do not infer recall status, a Warning Letter, or a final inspection classification from a 483 alone.

For structured follow-up, use our member planning templates or discuss Form 483 response support. These examples support focused review, not claims about the most frequent findings across FDA inspections.

Related September reviews

Sources reviewed October 20, 2026. This is independent editorial analysis of selected public records, not an FDA publication, a complete activity count, or a determination of any firm’s current compliance.